The Supreme Court has instructed Zydus Lifesciences to approach the Delhi High Court. Zydus is seeking relief from an order ...

In July, a single-judge bench of the Delhi High Court restrained Zydus Lifesciences from selling its breast cancer drug in ...

Sharekhan is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 1078 in its ...

Zydus Lifesciences Q2 Results Live : Zydus Lifesciences declared their Q2 results on 12 Nov, 2024, reporting a notable ...

Legal battle over Zydus' biosimilar breast cancer drug could impact generic competition, Supreme Court refuses interim relief ...

Zydus had approached the Supreme Court challenging the Delhi High Court's order, which prevented the company from producing ...

Zydus Lifesciences(NSEI:ZYDUSLIFE) has reported strong earnings growth, with a 65% increase, positioning it as a leader in the pharmaceutical sector. Recent developments include the World Health ...

Motilal Oswal recommended Neutral rating on Zydus LifeSciences with a target price of Rs 1010 in its research report dated ...

The Delhi High Court recently restored a single-judge order restraining Indian Pharma company Zydus Lifesciences ...

Upholding the patent rights of Swiss pharmaceutical giant F-Hoffmann-La Roche AG, the Delhi High Court has once again ...